VCRE (Vicore Pharma Holding AB) Shiller PE Ratio: (As of Aug. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VCRE Vicore Pharma Holding AB VCRE
13 GF Score
Price $12.50
! 2 Warning Signs
View Full Analysis

What is Vicore Pharma Holding AB Shiller PE Ratio?

Note: If the price history is too short, we do not calculate current Shiller PE for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Vicore Pharma Holding AB  (NAS:VCRE) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Vicore Pharma Holding AB Shiller PE Ratio Related Terms


Vicore Pharma Holding AB Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Vicore Pharma Holding AB's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vicore Pharma Holding AB Shiller PE Ratio Chart

Vicore Pharma Holding AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Vicore Pharma Holding AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

VCRE vs VRTX, REGN, RVMD: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Vicore Pharma Holding AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vicore Pharma Holding AB Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vicore Pharma Holding AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Vicore Pharma Holding AB's Shiller PE Ratio falls into.


VCRE
13GF Score
Vicore Pharma Holding AB VCRE
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vicore Pharma Holding AB Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Vicore Pharma Holding AB's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, Vicore Pharma Holding AB's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.536/134.6100*134.6100
=-0.536

Current CPI (Jun. 2026) = 134.6100.

Vicore Pharma Holding AB Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 -0.100 101.138 -0.133
201612 -0.135 102.022 -0.178
201703 -0.153 102.022 -0.202
201706 -0.148 102.752 -0.194
201709 -0.134 103.279 -0.175
201712 -1.183 103.793 -1.534
201803 -0.012 103.962 -0.016
201806 0.442 104.875 0.567
201809 -0.707 105.679 -0.901
201812 -0.582 105.912 -0.740
201903 -0.419 105.886 -0.533
201906 -0.652 106.742 -0.822
201909 -0.541 107.214 -0.679
201912 -0.619 107.766 -0.773
202003 -0.554 106.563 -0.700
202006 -0.502 107.498 -0.629
202009 -0.714 107.635 -0.893
202012 -1.175 108.296 -1.461
202103 -0.866 108.360 -1.076
202106 -1.136 108.928 -1.404
202109 -1.531 110.338 -1.868
202112 -1.199 112.486 -1.435
202203 -1.322 114.825 -1.550
202206 -0.892 118.384 -1.014
202209 -0.847 122.296 -0.932
202212 -0.769 126.365 -0.819
202303 -0.752 127.042 -0.797
202306 -0.768 129.407 -0.799
202309 -0.509 130.224 -0.526
202312 -0.965 131.912 -0.985
202403 0.269 132.205 0.274
202406 -0.477 132.716 -0.484
202409 -0.518 132.304 -0.527
202412 -0.364 132.987 -0.368
202503 -0.474 132.825 -0.480
202506 -0.513 133.699 -0.516
202509 -0.512 133.480 -0.516
202512 -0.581 133.390 -0.586
202603 -0.419 133.560 -0.422
202606 -0.536 134.610 -0.536

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Vicore Pharma Holding AB Business Description

Other Exchanges VICO:Sweden6Y4:Germany
Address Kornhamnstorg 53, Stockholm, SWE, 111 27
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
13GF Score

Get the complete analysis for VCRE

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.50
Price